Billiontoone Inc 's

The company operates in the prenatal testing market with its UNITY product, which addresses comprehensive prenatal genetic needs through a single maternal blood draw. While some competitors have introduced non-invasive prenatal tests (NIPTs) for recessive conditions, the company cites its smNGS technology and accumulated data as competitive advantages. In oncology, the company launched two pan-cancer liquid biopsy tests, Northstar Select and Northstar Response, in 2023. Northstar Select demonstrated higher sensitivity than leading competitors by detecting a greater number of actionable solid tumor mutations. The company identifies its patented smNGS platform and proprietary technologies as key differentiators. Additionally, it utilizes an innovative organizational structure and artificial intelligence to enhance productivity. A head-to-head concordance study submitted during the MolDX evaluation confirmed Northstar Select's superior sensitivity in detecting single nucleotide variants and copy number variants compared to leading competitors.